WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 534791
CAS#: 130656-51-8
Description: MS 551 is a bioactive chemical.
MedKoo Cat#: 534791
Name: MS 551
CAS#: 130656-51-8
Chemical Formula: C19H28ClN5O5
Exact Mass: 441.1779
Molecular Weight: 441.913
Elemental Analysis: C, 51.64; H, 6.39; Cl, 8.02; N, 15.85; O, 18.10
Synonym: MS 551; MS551; MS-551
IUPAC/Chemical Name: 2,4(1H,3H)-Pyrimidinedione, 6-((2-((2-hydroxyethyl)(3-(4-nitrophenyl)propyl)amino)ethyl)amino)-1,3-dimethyl-, monohydrochloride
InChi Key: YPVGGQKNWAKOPX-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H
SMILES Code: O=C1N(C)C(C=C(NCCN(CCO)CCCC2=CC=C([N+]([O-])=O)C=C2)N1C)=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 441.913 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cardiovasc Res. 1996 Jun;31(6):963-74. PMID: 8759253.
2: Sato R, Koumi S, Hisatome I, Takai H, Aida Y, Oyaizu M, Karasaki S, Mashiba H, Katori R. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1995 Jul;274(1):469-74. PMID: 7616432.
3: Isomoto S, Konoe A, Centurion OA, Hayano M, Kaibara M, Hirata T, Yano K. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. Pacing Clin Electrophysiol. 1995 Nov;18(11):2022-7. doi: 10.1111/j.1540-8159.1995.tb03863.x. PMID: 8552516.
4: Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. J Pharmacol Exp Ther. 1998 May;285(2):687-94. PMID: 9580614.
5: Chen J, Komori S, Li B, Tamura K, Hashimoto K. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol. 1996 Nov;119(5):937-42. doi: 10.1111/j.1476-5381.1996.tb15762.x. PMID: 8922743; PMCID: PMC1915953.
6: Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol. 1992 Feb;58(2):107-15. doi: 10.1254/jjp.58.107. PMID: 1507517.
7: Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993 May;109(1):157-63. doi: 10.1111/j.1476-5381.1993.tb13546.x. PMID: 7684298; PMCID: PMC2175592.
8: Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in Cardiac Arrest: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018 Mar;27(3):280-290. doi: 10.1016/j.hlc.2017.07.004. Epub 2017 Aug 23. PMID: 28988724.
9: Friedrichs GS, Chi L, Gralinski MR, Black SC, Basler GC, Mu DX, Pewitt SR, Johnson CR, Lucchesi BR. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol. 1995 Feb;25(2):314-23. doi: 10.1097/00005344-199502000-00018. PMID: 7752658.
10: Naitoh N, Tagawa M, Yamaura M, Taneda K, Furushima H, Aizawa Y. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias. Jpn Heart J. 1998 Jul;39(4):457-67. doi: 10.1536/ihj.39.457. PMID: 9810296.
11: Long B, Koyfman A. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. J Emerg Med. 2017 Apr;52(4):484-492. doi: 10.1016/j.jemermed.2016.09.010. Epub 2016 Oct 15. PMID: 27751700.
12: Uwabe K, Endo M, Nishida H, Tomizawa Y, Koyanagi H, Ohnishi S, Kasanuki H. [The effect of MS-551 on two VT/Vf patients in CABG: a case report]. Kyobu Geka. 1998 Feb;51(2):108-11. Japanese. PMID: 9492458.
13: Xue Y, Yamada C, Aye NN, Hashimoto K. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias. Br J Pharmacol. 1998 Aug;124(8):1712-8. doi: 10.1038/sj.bjp.0701987. PMID: 9756388; PMCID: PMC1565555.
14: Friedrichs GS, Chi L, Black SC, Manley PJ, Lucchesi BR. Antiarrhythmic agent, MS-551, protects against pinacidil + hypoxia-induced ventricular fibrillation in Langendorff-perfused rabbit isolated heart. J Cardiovasc Pharmacol. 1994 Jan;23(1):120-6. doi: 10.1097/00005344-199401000-00017. PMID: 7511723.
15: Suzuki K, Furukawa T, Koyama Y, Sagawa T, Nishimura M, Yamanaka M. Concentration-dependent block of sodium current in guinea pig ventricular myocytes by a class III antiarrhythmic agent, MS-551. J Cardiovasc Pharmacol. 1998 Nov;32(5):819-25. doi: 10.1097/00005344-199811000-00019. PMID: 9821857.
16: Naitoh N, Taneda K, Tagawa M, Furushima H, Yamaura M, Aizawa Y. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle. Jpn Heart J. 1998 May;39(3):297-305. doi: 10.1536/ihj.39.297. PMID: 9711181.
17: Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol. 1996 Jan;27(1):159-66. doi: 10.1097/00005344-199601000-00025. PMID: 8656651.
18: Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, Nakashima M. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994 Apr;23(4):674-80. doi: 10.1097/00005344-199404000-00024. PMID: 7516022.
19: Tanabe T, Iwamoto T, Iwata O, Aikawa M, Kusuzaki S, Handa S, Shinozaki Y, Mori H. Electrophysiologic and blood-flow responses in the endocardium and epicardium to disopyramide and MS-551 during myocardial ischemia in the dog. J Cardiovasc Pharmacol. 1999 Aug;34(2):275-86. doi: 10.1097/00005344-199908000-00014. PMID: 10445680.
20: Furutani K, Tsumoto K, Chen IS, Handa K, Yamakawa Y, Sack JT, Kurachi Y. Facilitation of IKr current by some hERG channel blockers suppresses early afterdepolarizations. J Gen Physiol. 2019 Feb 4;151(2):214-230. doi: 10.1085/jgp.201812192. Epub 2019 Jan 23. PMID: 30674563; PMCID: PMC6363420.
